Post-marketing surveillance and regulatory considerations in Japan MCQs With Answer

Introduction: This quiz set focuses on post-marketing surveillance and regulatory considerations in Japan, tailored for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T). It covers the Japanese regulatory landscape including the roles of the PMDA and MHLW, post-marketing safety systems, mandatory reporting obligations, Good Post-marketing Study Practice (GPSP), Risk Management Plans (RMPs), re-examination/re-evaluation concepts, and Japanese safety databases such as JADER. The questions reinforce understanding of practical obligations for Marketing Authorization Holders (MAHs), types of post-marketing studies, special approval pathways (e.g., Sakigake), and how pharmacovigilance activities are organized and evaluated in Japan. These MCQs include answers and concise focus on applied regulatory practice.

Q1. What is the primary Japanese agency responsible for post-marketing safety oversight of pharmaceuticals?

• Pharmaceuticals and Medical Devices Agency (PMDA)
• Japan Food Safety Commission
• National Institute of Health Sciences (NIHS)
• Ministry of Economy, Trade and Industry (METI)

Correct Answer: Pharmaceuticals and Medical Devices Agency (PMDA)

Q2. Which ministry issues final regulatory decisions and ministerial ordinances for drug approvals and post-marketing measures in Japan?

• Ministry of Health, Labour and Welfare (MHLW)
• Ministry of Education, Culture, Sports, Science and Technology (MEXT)
• Ministry of Finance
• Ministry of Internal Affairs and Communications

Correct Answer: Ministry of Health, Labour and Welfare (MHLW)

Q3. Which Japanese guidance defines standards for conducting post-marketing clinical investigations and surveillance?

• Good Post-marketing Study Practice (GPSP)
• Good Manufacturing Practice (GMP)
• Good Clinical Practice (GCP)
• Good Distribution Practice (GDP)

Correct Answer: Good Post-marketing Study Practice (GPSP)

Q4. What is the main purpose of a Risk Management Plan (RMP) submitted to PMDA at approval?

• To outline identified and potential safety issues and planned risk minimization and pharmacovigilance activities
• To provide manufacturing batch release procedures
• To request pricing and reimbursement information
• To define the marketing strategy and promotional materials

Correct Answer: To outline identified and potential safety issues and planned risk minimization and pharmacovigilance activities

Q5. Which Japanese database publicly provides adverse event reports submitted to PMDA?

• JADER (Japanese Adverse Drug Event Report database)
• Vigibase
• FAERS
• EudraVigilance

Correct Answer: JADER (Japanese Adverse Drug Event Report database)

Q6. Under post-marketing obligations, who is primarily responsible for collecting and reporting adverse drug reactions to PMDA?

• Marketing Authorization Holder (MAH)
• Individual prescribing physicians
• Hospital pharmacists only
• Contract research organizations (CROs) exclusively

Correct Answer: Marketing Authorization Holder (MAH)

Q7. Which of the following best describes the regulatory concept of re-examination in Japan?

• A post-marketing evaluation period to collect additional efficacy and safety data after approval
• A pre-approval toxicology requirement for new chemical entities
• A manufacturing inspection program for foreign facilities
• A pricing reassessment for marketed drugs

Correct Answer: A post-marketing evaluation period to collect additional efficacy and safety data after approval

Q8. What type of post-marketing study in Japan is specifically guided by GPSP and focuses on safety in real-world use?

• Post-marketing surveillance (PMS) observational studies
• Phase I clinical trials
• Bioequivalence crossover studies
• Pre-clinical animal toxicology studies

Correct Answer: Post-marketing surveillance (PMS) observational studies

Q9. The Sakigake designation in Japan is intended to:

• Prioritize regulatory review and support for innovative products developed in Japan
• Limit foreign companies from filing in Japan
• Extend patent exclusivity automatically
• Require additional clinical trials for all generics

Correct Answer: Prioritize regulatory review and support for innovative products developed in Japan

Q10. Which activity is a typical element of a post-marketing Risk Minimization Action Plan (part of an RMP) in Japan?

• Targeted educational programs for healthcare professionals on safe use
• Changing the inert ingredients of a formulation
• Conducting only pre-clinical animal studies
• Providing free samples to patients

Correct Answer: Targeted educational programs for healthcare professionals on safe use

Q11. Which report type summarizes accumulated safety data periodically during the post-marketing phase and is required internationally and in Japan?

• Periodic Safety Update Report (PSUR)
• Investigator’s Brochure
• Clinical Study Report (CSR)
• Common Technical Document (CTD) Module 3

Correct Answer: Periodic Safety Update Report (PSUR)

Q12. Which of the following best describes GPSP inspections performed by PMDA?

• Audits of MAH-conducted post-marketing studies to ensure compliance with GPSP standards
• Routine inspections of hospital pharmacies for drug pricing
• Annual inspections of foreign manufacturing facilities only
• Marketing audits for promotional content

Correct Answer: Audits of MAH-conducted post-marketing studies to ensure compliance with GPSP standards

Q13. When a new safety signal is detected in post-marketing data, PMDA may require the MAH to:

• Conduct additional targeted post-marketing studies and update the RMP
• Withdraw all marketing authorization for unrelated products
• Change the company’s board of directors
• Delay all ongoing clinical trials worldwide

Correct Answer: Conduct additional targeted post-marketing studies and update the RMP

Q14. Which mechanism allows limited approval in Japan for regenerative medicine products with evidence of probable benefit while requiring post-marketing data collection?

• Conditional and time-limited authorization applicable to regenerative medical products
• Traditional approval pathway requiring full phase III trials before marketing
• Orphan drug exclusivity program only
• Patent term extension pathway

Correct Answer: Conditional and time-limited authorization applicable to regenerative medical products

Q15. What is a common source of post-marketing safety information that MAHs must monitor continuously?

• Spontaneous adverse reaction reports from healthcare professionals and patients
• Only pre-approval phase III trial datasets
• Advertising expenditure reports
• Manufacturing internal memos

Correct Answer: Spontaneous adverse reaction reports from healthcare professionals and patients

Q16. Which of the following best characterizes a Post-Authorization Safety Study (PASS) requested by PMDA?

• A study specifically designed to address identified or potential safety concerns in the real-world setting
• A bioequivalence study for a generic drug
• An in vitro stability study for packaging materials
• A study to evaluate marketing preferences among physicians

Correct Answer: A study specifically designed to address identified or potential safety concerns in the real-world setting

Q17. In Japan, which document should be updated and submitted to notify labeling changes related to newly identified risks?

• Package insert (PI) / labeling and the Japanese prescribing information
• Marketing brochure only
• Manufacturing batch record
• Company annual financial report

Correct Answer: Package insert (PI) / labeling and the Japanese prescribing information

Q18. Which stakeholder is expected to actively report adverse events to MAHs or PMDA in Japan?

• Healthcare professionals, including physicians and pharmacists
• Only company sales representatives
• Only clinical trial investigators after market withdrawal
• Only patients with rare diseases

Correct Answer: Healthcare professionals, including physicians and pharmacists

Q19. The purpose of re-evaluation of an older marketed drug in Japan is to:

• Review accumulated safety and efficacy information to determine continued benefit-risk balance
• Increase the wholesale price automatically
• Convert it into an over-the-counter product regardless of data
• Extend exclusivity without additional evidence

Correct Answer: Review accumulated safety and efficacy information to determine continued benefit-risk balance

Q20. Which practice supports signal detection and trend analysis in Japan’s pharmacovigilance system?

• Routine analysis of spontaneous report databases such as JADER and safety databases maintained by MAHs
• Relying solely on social media posts without validation
• Only reviewing pre-approval clinical data annually
• Publishing promotional materials before safety review

Correct Answer: Routine analysis of spontaneous report databases such as JADER and safety databases maintained by MAHs

Download